514 related articles for article (PubMed ID: 10485449)
1. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.
Yeager TR; Neumann AA; Englezou A; Huschtscha LI; Noble JR; Reddel RR
Cancer Res; 1999 Sep; 59(17):4175-9. PubMed ID: 10485449
[TBL] [Abstract][Full Text] [Related]
2. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
3. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
4. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body.
Nabetani A; Yokoyama O; Ishikawa F
J Biol Chem; 2004 Jun; 279(24):25849-57. PubMed ID: 15075340
[TBL] [Abstract][Full Text] [Related]
5. De novo assembly of a PML nuclear subcompartment occurs through multiple pathways and induces telomere elongation.
Chung I; Leonhardt H; Rippe K
J Cell Sci; 2011 Nov; 124(Pt 21):3603-18. PubMed ID: 22045732
[TBL] [Abstract][Full Text] [Related]
6. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
[TBL] [Abstract][Full Text] [Related]
7. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
[TBL] [Abstract][Full Text] [Related]
8. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference.
Jiang WQ; Zhong ZH; Henson JD; Reddel RR
Oncogene; 2007 Jul; 26(32):4635-47. PubMed ID: 17297460
[TBL] [Abstract][Full Text] [Related]
9. PML and TRF2 protein expression in hereditary and sporadic colon cancer.
Plevová P; Bouchal J; Fiurásková M; Papezová M; Krepelová A; Curík R; Foretová L; Navrátilová M; Zapletalová J; Posolda T; Kolár Z
Neoplasma; 2007; 54(4):269-77. PubMed ID: 17822315
[TBL] [Abstract][Full Text] [Related]
10. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1.
Wu G; Jiang X; Lee WH; Chen PL
Cancer Res; 2003 May; 63(10):2589-95. PubMed ID: 12750284
[TBL] [Abstract][Full Text] [Related]
11. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells.
Yu J; Lan J; Wang C; Wu Q; Zhu Y; Lai X; Sun J; Jin C; Huang H
Cancer Lett; 2010 May; 291(2):177-86. PubMed ID: 19900757
[TBL] [Abstract][Full Text] [Related]
12. Alternative lengthening of telomeres in mammalian cells.
Henson JD; Neumann AA; Yeager TR; Reddel RR
Oncogene; 2002 Jan; 21(4):598-610. PubMed ID: 11850785
[TBL] [Abstract][Full Text] [Related]
13. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle.
Grobelny JV; Godwin AK; Broccoli D
J Cell Sci; 2000 Dec; 113 Pt 24():4577-85. PubMed ID: 11082050
[TBL] [Abstract][Full Text] [Related]
14. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
[TBL] [Abstract][Full Text] [Related]
15. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD; Hannay JA; McCarthy SW; Royds JA; Yeager TR; Robinson RA; Wharton SB; Jellinek DA; Arbuckle SM; Yoo J; Robinson BG; Learoyd DL; Stalley PD; Bonar SF; Yu D; Pollock RE; Reddel RR
Clin Cancer Res; 2005 Jan; 11(1):217-25. PubMed ID: 15671549
[TBL] [Abstract][Full Text] [Related]
16. Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines.
French JD; Dunn J; Smart CE; Manning N; Brown MA
Genes Chromosomes Cancer; 2006 Mar; 45(3):277-89. PubMed ID: 16283620
[TBL] [Abstract][Full Text] [Related]
17. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.
Plantinga MJ; Pascarelli KM; Merkel AS; Lazar AJ; von Mehren M; Lev D; Broccoli D
Mol Cancer Res; 2013 Jun; 11(6):557-67. PubMed ID: 23505069
[TBL] [Abstract][Full Text] [Related]
18. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
19. DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA.
Fasching CL; Neumann AA; Muntoni A; Yeager TR; Reddel RR
Cancer Res; 2007 Aug; 67(15):7072-7. PubMed ID: 17652140
[TBL] [Abstract][Full Text] [Related]
20. hRad21 overexpresses and localizes to the ALT-associated promyelocytic leukemia body in ALT cells.
Zhao B; Wang ZJ; Yi BQ; Ma HC; Xu HM
Cancer Biol Ther; 2010 Jun; 9(12):978-83. PubMed ID: 20364118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
